CNCE:NSD-Concert Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.69

Change

-0.18 (-2.62)%

Market Cap

USD 0.21B

Volume

0.28M

Average Target Price

USD 17.00 (+154.11%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.

Company Website : http://www.concertpharma.com

Address : 65 Hayden Avenue, Lexington, MA, United States, 02421

Employees : 70

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.69

52 Week High : 13.44

Short Ratio : 0.75

52 Week Low : 5.47

Shorted Shares : 585,095

200 Day Moving Average : 10.47

Shorted Shares Previous Month : 961,473

50 Day Moving Average : 9.05

Shares Held By Insiders : 102.51%

Short Percentage : 2.00%

Shares Held by Institutions : 70.92%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+6.43 (+4.33%)

 USD58.72B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.43 (-0.20%)

 USD55.37B 20.70 14.64
REGN Regeneron Pharmaceuticals, Inc

-2.62 (-0.58%)

 USD48.55B 14.85 12.06
ALXN Alexion Pharmaceuticals, Inc

-0.90 (-0.59%)

 USD33.78B 56.49 34.28
BGNE BeiGene, Ltd

-9.73 (-2.95%)

 USD29.41B N/A N/A
RPRX Royalty Pharma plc

-0.45 (-0.96%)

 USD28.55B 22.60 14.73
BNTX BioNTech SE

-3.30 (-2.94%)

 USD27.49B -99,999.99 N/A
SGEN Seagen Inc

+1.02 (+0.68%)

 USD27.19B 44.54 41.48
GMAB Genmab A/S

+0.19 (+0.56%)

 USD23.40B 26.59 3.51
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing CNCE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.07% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.07% 1% F 1% F
Trailing 12 Months  
Capital Gain -20.92% 19% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.92% 19% F 8% F
Trailing 5 Years  
Capital Gain -49.05% 29% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.05% 29% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain 9.09% 50% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.09% 50% F 59% F
Risk Return Profile  
Volatility (Standard Deviation) 53.62% 52% F 25% F
Risk Adjusted Return 16.96% 49% F 44% F
Market Capitalization 0.21B 33% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3.30 59% F 86% B
Price/Book Ratio 1.76 92% A- 69% D+
Price / Cash Flow Ratio -4.32 29% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -58.95% 55% F 20% F
Return on Invested Capital -58.70% 52% F 17% F
Return on Assets -29.52% 45% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.75 73% C 71% C-
Short Percent 2.15% 82% B- 61% D-
Beta 0.69 81% B- 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector